Immunotherapy is an active area in cancer research and is advantageous compared to traditional therapies in certain ways, such as its high effectivity, reduced relapse risk, less toxicity, etc. Current studies implicate the potential participation of Cyclin K in cancer immunotherapy. The gene discussed is CCNK; the disease is cancer.